Next report date
Report period
Q1 2024
EPS estimate
−6.96MXN
Revenue estimate
1.16 BMXN
−68.38MXN
−2.78 BMXN
3.17 BMXN
37.00 M
About Mirum Pharmaceuticals, Inc.
Sector
CEO
Christopher Peetz
Headquarters
Foster City
Website
Employees (FY)
264
Founded
2018
FIGI
BBG0121CJQL5
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MIRM is 479.15 MXN — it has decreased by 10.53% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange MIRUM PHARMACEUTICALS INC stocks are traded under the ticker MIRM.
MIRUM PHARMACEUTICALS INC is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
MIRM stock is 11.77% volatile and has beta coefficient of 0.65. Check out the list of the most volatile stocks — is MIRUM PHARMACEUTICALS INC there?
MIRM earnings for the last quarter are −9.94 MXN per share, whereas the estimation was −10.95 MXN resulting in a 9.27% surprise. The estimated earnings for the next quarter are −4.08 MXN per share. See more details about MIRUM PHARMACEUTICALS INC earnings.
MIRUM PHARMACEUTICALS INC revenue for the last quarter amounts to 831.88 M MXN despite the estimated figure of 672.82 M MXN. In the next quarter revenue is expected to reach 1.15 B MXN.
Yes, you can track MIRUM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
MIRM net income for the last quarter is −563.04 M MXN, while the quarter before that showed −411.16 M MXN of net income which accounts for −36.94% change. Track more MIRUM PHARMACEUTICALS INC financial stats to get the full picture.
Today MIRUM PHARMACEUTICALS INC has the market capitalization of 20.11 B, it has decreased by 6.06% over the last week.
No, MIRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MIRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MIRUM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 264.00 employees. See our rating of the largest employees — is MIRUM PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MIRUM PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MIRUM PHARMACEUTICALS INC stock shows the strong buy signal. See more of MIRUM PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MIRUM PHARMACEUTICALS INC future price: according to them, MIRM price has a max estimate of 1204.07 MXN and a min estimate of 568.59 MXN. Read a more detailed MIRUM PHARMACEUTICALS INC forecast: see what analysts think of MIRUM PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MIRUM PHARMACEUTICALS INC EBITDA is −1.62 B MXN, and current EBITDA margin is −52.76%. See more stats in MIRUM PHARMACEUTICALS INC financial statements.